Trial · NCT06150898
Ketorolac and Pregabalin Effects on breaSt Cancer (KePreSt)
NCT06150898, Phase 2, Recruiting, Jules Bordet Institute
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Ketorolac and Pregabalin Effects on breaSt Cancer (KePreSt). Trials, record NCT06150898. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06150898
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Ketorolac and Pregabalin Effects on breaSt Cancer (KePreSt)
- NCT number
- NCT06150898
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 112 participants, estimated
- Lead sponsor
- Jules Bordet Institute
- Conditions
- Early-stage Breast Cancer, Estrogen-receptor-positive Breast Cancer
- Interventions
- Prospective data and sample collection, Ketorolac 10 Mg Oral Tablet, Pregabalin 75mg, Omeprazole 20mg Capsule
- First posted
- 2023-11-29
- Last updated
- 2026-10-09
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | To detect a reduced increase in systemic inflammation (from baseline to up to 24 hours after surgery) using peri-operative ketorolac | Up to 24 hours after surgery | Plasma multiplex technology using cytometric bead arrays |
| Primary | To detect a reduced increase in systemic neurotransmitters (from baseline to up to 24 hours after surgery) using peri-operative pregabalin | Up to 24 hours after surgery | Liquid Chromatography coupled to tandem Mass Spectrometry (LC-MS/MS) |
| Primary | Change in biomarkers of metastasis at surgery from baseline | At surgery | Transcriptome profile and bioinformatic analysis |
| Primary | Change in tumoral immune cells recruitment at surgery from baseline | At surgery | Characterization of Tumour-infiltrating leukocyte subpopulations using RNA sequencing analysis from fresh frozen tissue sections |
| Primary | Change in tumoral neurogenesis at surgery from baseline | At surgery | Level of neurogenesis markers using RNA sequencing analysis from fresh frozen tissue section |
| Primary | Change in tumoral neurotransmitters level at surgery from baseline | At surgery | Using RNA sequencing analysis from fresh frozen tissue sections |
| Primary | Change in Peripheral Blood Mononuclear Cells at surgery from baseline | At surgery | Fluorescence activated cell sorting (FACS) analysis |
| Primary | Change in systemic neuro-inflammatory mediators at surgery from baseline | At surgery | Plasma multiplex technology using cytometric bead arrays |
| Primary | Change in systemic neurotransmitters at surgery from baseline | At surgery | Plasma multiplex technology using cytometric bead arrays |
| Secondary | Change in anxiety level at surgery from baseline | At surgery | Generalized Anxiety Disorder - 7 (GAD - 7) Anxiety score (natural number, range\[0 - 21\]. A score comprised between 0 - 4 indicates a minimal anxiety, 5-9 a mild anxiety, 10-14 a moderate anxiety and a 15-21 in a severe anxiety. |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06150898
GET https://conductscience.org/api/trials/v1/NCT06150898/registered